ArticleAdvances in therapy2021

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina.

Victoria Wurcel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.